Chugai Pharma Obtains Japanese Approval For FoundationOne CDx Cancer Genomic Profile As CDx For Pemigatinib In Patients With Biliary Tract Cancer

Chugai Pharmaceutical announced that it obtained approval from the Ministry of Health, Labour and Welfare (MHLW) for the use of FoundationOne CDx Cancer Genomic Profile as a companion diagnostic (CDx) for the fibroblast growth factor receptor (FGFR) inhibitor pemigatinib, for patients with FGFR2 fusion positive locally advanced or metastatic biliary tract cancer on February 15, 2021.“We are very pleased that FoundationOne CDx Cancer Genomic Profile has been approved as a companion diagnostic for pemigatinib in patients with biliary tract cancer. The expanded use of FoundationOne CDx Cancer Genomic Profile for this new cancer type with high unmet medical needs underscores the value of comprehensive genomic profiling in cancer treatment,” said Dr. Osamu Okuda, Chugai’s president and COO. “We are committed to preparing for the use of the genomic profiling to identify those who may benefit from pemigatinib.”The approval allows the use of FoundationOne CDx Cancer Genomic Profile as a companion diagnostic to identify patients with FGFR2 fusion positive locally advanced or metastatic biliary tract cancer who could benefit from treatment with pemigatinib. Incyte Biosciences Japan submitted a Japanese New Drug Application for pemigatinib for the treatment of FGFR2 fusion positive locally advanced or metastatic cholangiocarcinoma with the MHLW on September 14, 2020 which is currently under review. The MHLW granted orphan drug designation to pemigatinib for this indication.As a leading company in the field of oncology, Chugai is committed to realizing advanced personalized oncology care and contributing to patients and healthcare professionals through improving access to comprehensive genomic profiling of cancers.Fibroblast growth factor receptors (FGFRs) play an important role in tumor cell proliferation and survival, migration and angiogenesis (the formation of new blood vessels). Activating mutations, translocations and gene amplifications in FGFRs are closely correlated with the development of various cancers.Chugai Pharmaceutical announced that it obtained approval from the Ministry of Health, Labour and Welfare (MHLW) for the use of FoundationOne CDx Cancer Genomic Profile as a companion diagnostic (CDx) for the fibroblast growth factor receptor (FGFR) inhibitor pemigatinib, for patients with FGFR2 fusion positive locally advanced or metastatic biliary tract cancer on February 15, 2021. “We are very pleased that FoundationOne CDx Cancer Genomic Profile has been approved as a companion diagnostic for pemigatinib in patients with biliary tract cancer. The expanded use of FoundationOne CDx Cancer Genomic Profile for this new cancer type with high unmet medical needs underscores the value of comprehensive genomic profiling in cancer treatment,” said Dr. Osamu Okuda, Chugai’s president and COO. “We are committed to preparing for the use of the genomic profiling to identify those who may benefit from pemigatinib.”The approval allows the use of FoundationOne CDx Cancer Genomic Profile as a companion diagnostic to identify patients with FGFR2 fusion positive locally advanced or metastatic biliary tract cancer who could benefit from treatment with pemigatinib. Incyte Biosciences Japan submitted a Japanese New Drug Application for pemigatinib for the treatment of FGFR2 fusion positive locally advanced or metastatic cholangiocarcinoma with the MHLW on September 14, 2020 which is currently under review. The MHLW granted orphan drug designation to pemigatinib for this indication.As a leading company in the field of oncology, Chugai is committed to realizing advanced personalized oncology care and contributing to patients and healthcare professionals through improving access to comprehensive genomic profiling of cancers.Fibroblast growth factor receptors (FGFRs) play an important role in tumor cell proliferation and survival, migration and angiogenesis (the formation of new blood vessels). Activating mutations, translocations and gene amplifications in FGFRs are closely correlated with the development of various cancers.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!